TABLE A4.
Multivariable association of patient characteristics with delayed methotrexate elimination at 48 h
| Characteristic | Odds ratio (95% CI)a | p-Value |
|---|---|---|
| Levetiracetam | 1.73 (1.01, 2.98) | 0.047 |
| Age (year) | 1.05 (1.02, 1.07) | <0.001 |
| Male | 1.22 (0.68, 2.16) | 0.50 |
| Race | ||
| Caucasian | 1.04 (0.41, 2.63) | 0.93 |
| Other/unknown | Reference | |
| Body surface area, m2 | 1.20 (1.09, 1.33)b | <0.001 |
| Lymphoma diagnosis subtype | ||
| DLBCL | Reference | |
| Primary DLBCL of the CNS | 1.14 (0.67, 1.92) | 0.63 |
| Other | 1.20 (0.50, 2.87) | 0.68 |
| Intended HDMTX dose, g/m2 | ||
| 3.5 | Reference | |
| 8 | 1.72 (0.87, 3.42) | 0.12 |
| Other | 0.47 (0.03, 8.79) | 0.62 |
| HDMTX dose, g | 1.13 (1.04, 1.22) | 0.003 |
| Serum creatinine, mg/dl | 1.21 (1.10, 1.34) | <0.001 |
| Hemoglobin, g/dl | 0.68 (0.59, 0.77) | <0.001 |
| Total bilirubin, mg/dl | 1.08 (1.02, 1.15)b | 0.007 |
Abbreviations: CI, confidence interval; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; HDMTX, high-dose methotrexate.
a
Odds ratios for continuous variables are per 1 unit increase unless otherwise specified.
b
Per 0.1 unit increase.